This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.1 | Synonyms: BSS, Giant platelet syndrome, GP Ib-IX-V complex deficiency
In 1948, the French hematologists Jean Bernard and Jean-Pierre Soulier first described a syndrome characterized by a severe bleeding tendency, thrombocytopenia, and giant platelets. They noted that this syndrome showed a serious bleeding tendency that could not be explained by the reduced platelet count alone, and were the first to record that it is accompanied by a distinctive abnormality of platelet morphology (giant platelets).
With advances in research on platelet surface glycoproteins in the 1970s, it was found that GP Ib is deficient in the platelets of BSS patients. In 1975, Nurden and Caen demonstrated that GP Ib is selectively deficient in the platelets of BSS patients and that it is essential for platelet adhesion through binding to von Willebrand factor (vWF).
With advances in molecular biology techniques in the 1990s, the entire GP Ib-IX-V complex, composed of GP Ibα, GP Ibβ, GP IX, and GP V, was characterized. It was found that in BSS, if any one of the glycoproteins making up this complex is deficient or dysfunctional, the entire complex is not expressed on the platelet membrane. Subsequently, molecular analysis of GP1BA, GP1BB, and GP9 gene mutations became the diagnostic standard.
BSS is an autosomal recessive genetic disease caused by mutations in the genes that make up the GP Ib-IX-V complex. Related genes: GP1BA (GP Ibα, 17p13.2), GP1BB (GP Ibβ, 22q11.21), GP9 (GP IX, 3q21.3). BSS due to mutation of the GP5 (GP V) gene alone is very rare. Various types of mutations have been reported, including missense, nonsense, frameshift, and splicing variants.
When there is deficiency of GP Ibα alone or of GP Ibβ or GP IX, the remaining component proteins also become unstable, and eventually the entire complex is not expressed on the platelet surface. Because this complex is linked to the cytoskeleton (filamin A) and is also involved in maintaining platelet size and shape, giant platelets form when the complex is deficient.
In DiGeorge/22q11.2 deletion syndrome, platelet dysfunction can occur owing to hemizygosity of the GP1BB gene, and this is sometimes classified as atypical BSS.
Typical BSS is inherited in an autosomal recessive manner. Heterozygous carriers usually have no clinical symptoms or only mild platelet dysfunction. When parents are consanguineous, the incidence of homozygous variants is high.
GP1BA gene: most common, with various variants including missense, nonsense, frameshift, and splicing variants. A specific founder variant has been reported particularly in an Iranian Jewish population. GP9 gene: the Asn45Ser variant has been reported repeatedly in several populations (hotspot mutation).
BSS also occurs in compound heterozygotes who carry one each of two different GP1BA or GP9 variants.
BSS is a very rare disease, reported in only about 200–300 families worldwide. The exact prevalence is unknown but is estimated at about 1 per million or less.
The incidence is relatively high in the Middle East, Iran, India, and some Mediterranean countries where consanguineous marriage is common. Several cases of BSS due to GP1BA variants have been reported in a particular Iranian Jewish population.
In Korea, BSS is extremely rare, and reported cases are very few. It is included in the national rare disease registration system, and case reports are being made mainly through the Korean Society of Hematology. In Korea as well, molecular diagnosis is becoming possible with the spread of next-generation sequencing.
The GP Ib-IX-V complex is a major receptor expressed on the platelet surface at about 25,000 copies. When a blood vessel is injured, the A1 domain of exposed vWF binds to the N-terminal leucine-rich repeat (LRR) domain of GP Ibα, mediating primary adhesion of platelets. This process is essential for platelet adhesion particularly under high shear stress (arterial environment).
When the GP Ib-IX-V complex is deficient: ① platelets cannot adhere to the vessel wall via vWF, ② response to thrombin is reduced, ③ signaling is abnormal, and ④ thrombocytopenia and giant platelet formation due to abnormal platelet production occur.
The GP Ib-IX-V complex is involved in maintaining platelet size and shape through its connection to the platelet cytoskeleton. When this complex is deficient, separation from megakaryocytes during platelet production occurs abnormally, producing giant platelets (3–20 μm in diameter). Giant platelets are rapidly destroyed in the spleen, resulting in thrombocytopenia.
The bleeding tendency in BSS ranges from mild to life-threatening. The most common symptom is mucosal bleeding, with epistaxis and gum bleeding appearing from childhood. Menorrhagia is a major symptom in female patients. Excessive bleeding occurs with surgery, tooth extraction, and trauma. Rarely, spontaneous intracranial hemorrhage and gastrointestinal bleeding can occur.
Some patients experience serious bleeding from early infancy, whereas some mild cases are not diagnosed until adulthood. Severity can differ even between siblings with the same mutation.
Cutaneous purpura, petechiae, ecchymoses. Traces of intranasal bleeding. Pallor due to anemia (with repeated bleeding). Splenomegaly is rarely present.
| Features | Bernard-Soulier syndrome | Glanzmann thrombasthenia |
|---|---|---|
| Platelet count | Decreased (thrombocytopenia) | Normal |
| Platelet size | Increased (giant platelets) | Normal |
| Ristocetin aggregation | Absent (GP Ib deficiency) | Normal (GP Ib normal) |
| ADP/collagen aggregation | Decreased (partial) | Completely absent |
| Clot retraction | Normal | Absent |
| Flow cytometry | CD42b (GP Ib) decreased | CD41/CD61 (GP IIb/IIIa) decreased |
Complete blood count (CBC): decreased platelet count (usually 30,000–100,000/μL) + markedly increased MPV. Giant platelets observed on peripheral blood smear. PFA-100: markedly prolonged closure time.
BSS should be suspected first when the three features of unexplained mucosal bleeding beginning in childhood + thrombocytopenia + giant platelets appear together, particularly when there is no drug history, vWD screening tests are normal, and ristocetin aggregation is decreased.
CBC + blood smear (confirmation of giant platelets). PFA-100 (confirmation of prolonged closure time). aPTT, PT (within normal range). Ristocetin aggregation test (decreased or absent). vWF antigen and activity (to exclude vWD).
Ristocetin mixing correction test: differentiation is possible by normal aggregation with normal platelets + patient plasma (vWF normal) and decreased aggregation with patient platelets + normal plasma (confirming platelet GP Ib deficiency).
Flow cytometry: confirmation of markedly decreased platelet surface expression (5–20% of normal or less) with anti-CD42b (GP Ibα) and anti-CD42a (GP IX) antibodies is the key diagnostic method. CD62P (P-selectin) expression after activation is normal, so alpha-granule function is preserved.
Pathogenic variants are confirmed by sequencing of the GP1BA, GP1BB, and GP9 genes. NGS panel-based genetic testing for platelet function disorders can also be used.
MYH9-related platelet disorder: giant platelets + thrombocytopenia are similar, but inclusion bodies (Dohle bodies) are observed in leukocytes. Type 2B von Willebrand disease or platelet-type vWD: ristocetin aggregation is instead increased. Immune thrombocytopenia (ITP): giant platelets are rare, and antiplatelet antibodies are positive.
Antifibrinolytics (tranexamic acid): used for mucosal bleeding and perioperatively. Oral contraceptives: effective for controlling menorrhagia. DDAVP (desmopressin): shortens bleeding time in some patients, but because its effect cannot be predicted, a prior trial dose is recommended. Iron supplementation if iron-deficiency anemia develops.
Platelet transfusion is needed for serious bleeding or surgery. With repeated transfusions, alloantibody formation against GP Ibα can cause transfusion refractoriness. Transfusion of HLA-matched and crossmatch-compatible platelets is considered.
Use of rFVIIa (NovoSeven) has been reported in severe bleeding refractory to platelet transfusion; it may be effective for hemostasis by directly increasing thrombin generation on the platelet surface.
In patients with severe BSS who have recurrent severe bleeding and refractoriness to platelet transfusion, allogeneic HSCT is considered as a curative option. Transplant-related risks must be fully considered.
The bleeding tendency in BSS persists throughout life, but with appropriate management most patients can survive into adulthood. Severe bleeding episodes can rarely be a cause of death. Iron overload and alloimmunization due to repeated transfusions can occur as long-term complications.
Because the risk of obstetric bleeding during pregnancy is high, thorough planning before delivery and consultation with a hematologist are essential. With appropriate preventive treatment and delivery planning, a safe pregnancy outcome can be expected.
Drugs with antiplatelet action such as aspirin and NSAIDs are contraindicated. Prevention of trauma and restriction of contact sports. Oral hygiene care to minimize gum bleeding.
Consultation with a hematologist and preparation of platelet transfusion or rFVIIa before dental treatment, surgery, and delivery. Whether alloantibodies are present is checked in advance to plan the transfusion strategy.
Genetic counseling is provided to patients and families on the autosomal recessive mode of inheritance, the recurrence risk for siblings (25%), carrier testing, and the possibility of prenatal diagnosis.